VO₂max and strength for longevity
Cardiorespiratory fitness (VO₂max) & strength. Aging itself. Reviewed Jul 2026.
In large observational cohorts the top VO₂max quartile has about 4 to 5 times lower all-cause mortality than the bottom, and nothing pharmacological on this list comes close.
What it is
Raising VO₂max and muscle mass through zone-2 and high-intensity training plus resistance work — the most evidence-backed longevity lever available to anyone.
The evidence
Large cohort data: top-vs-bottom VO₂max quartile linked to ~4–5x lower all-cause mortality; grip strength and muscle mass independently predict longevity. Even ~4.4 min/day of vigorous movement links to 26–30% lower mortality.
What you can do today
This is available today. Whether it suits you depends on your health, your other medicines and your risks, so discuss it with a clinician who knows your history before starting or changing anything.
Sources
- Coverage, not a sourcex.com
No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.
Change history
No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.
Related
More in Aging itself
- Rapamycin for longevityExtends lifespan across many animal species, but there is no human outcome data for longevity and side effects such as poor wound healing and infection are real.
- Acarbose for longevityOne of the most reproducible lifespan extenders in mice, mainly in males, but there is no human longevity trial.
- RentosertibSix aging clocks moved in 42 lung-fibrosis patients over 12 weeks, a design that cannot separate slowed aging from a treated lung, and no healthy-volunteer or outcome data exist.
- Senolytics (dasatinib, quercetin, fisetin)Small human studies show the drugs can be given, with off-target side effects, but no durable benefit in people has been shown.
- Partial epigenetic reprogramming (ER-100)A first-in-human safety trial in the eye has started, but every efficacy result so far comes from animals.
- Therapeutic plasma exchange for agingA small trial lowered biological-age scores by about 1.3 years, a surrogate marker, and there is no outcome data.